– NEU Specialty Engineered Materials LLC, a subsidiary of PolyOne Corporation, today introduced NEU™ View Radiopaque Translucent Solutions for catheters at Medical Design & Manufacturing (MD&M) West. NEU View formulations for cardiovascular and intravascular catheters are application-specific, incorporating medical-grade polymers, additives, color, and healthcare-centric manufacturing practices.

As enterprise manufacturing footprints now extend globally, the demand for authentication technology keeps growing, especially in medical packaging, high-grade food packaging, consumer electronics and other industries. PolyOne Percept technologies include formulation and consultative services to assist manufacturers and brand owners in minimizing the potential risks and loss of revenue arising from counterfeits in applications such as consumer goods, medical devices, packaging, and consumer electronics.

Produced under rigorous cGMP and medical manufacturing protocols, the new amber color concentrates are made in three dedicated EN ISO 13485-2016 registered facilities using only medical-grade ingredients.

GUANGZHOU, China – PolyOne announced today at Chinaplas 2017 that COMPTEK™ blends based on polyetheretherketone (PEEK) are now available in Asia for multi-use medical devices, electrical connectors, and other demanding applications. The medical device manufacturing sector across Asia is growing quickly, and this region is also the clear leader in the manufacturing and export of electronics,” said Barto Du Plessis, vice president Asia, at PolyOne.

    Colorant Chromatics white colorants for high temperature polymers such as PPSU, PES, PSU and PEI to enhance aesthetics and performance of medical devices   •    Medical-grade thermoplastic elastomers that help customers to meet the requirements of demanding applications such IV tubing, bags and stoppers.

is a medical device manufacturer whose pain therapy products help patients manage pain and reduce the use of medications such as opiates.

To help customers manage their risk potential, dedicated facilities and systems govern the production of our medical colorants and performance masterbatches. Declarations based on pre-testing of the ingredients we use to standards typically required for medical and diagnostic devices (biological evaluations ISO10993, USP , for class VI devices); and for pharmaceutical packaging and drug-contacting materials (biological evaluation USP, EP chapter and requirements USP and ICHQ3D extractable metals).

To help customers manage their risk potential, dedicated facilities and systems govern the production of our medical colorants and performance masterbatches. Declarations based on pre-testing of the ingredients we use to standards typically required for medical and diagnostic devices (biological evaluations ISO10993, USP , for class VI devices); and for pharmaceutical packaging and drug-contacting materials (biological evaluation USP, EP chapter and requirements USP and ICHQ3D extractable metals).

CATEGORY DETAIL EC Number 231-545-4 CAS Number 7631-86-9 Chemical Name Silicon Dioxide (SiO2) Structural Formula CHEMICAL IDENTITY Si O O HEALTH EFFECTS HUMAN HEALTH SAFETY ASSESSMENT Consumer No human health hazard has been identified relating to this substance. EFFECT ASSESSMENT RESULT Aquatic Toxicity Not expected to be harmful to aquatic species Daphnia Toxicity Not acutely toxic to daphnia Bacteria Toxicity Not expected to be toxic to bacteria FATE BEHAVIOR Biodegradation Not possible as substance is inorganic Bioaccumulation Potential Low bioaccumulation potential expected PBT/vPvB Conclusion The substance is not a PBT/ vPvB substance EXPOSURE HUMAN HEALTH SAFETY ASSESSMENT Human Health No human health hazard was identified.

Adjusted earnings per share increased 42% to $0.44, marking the 18th consecutive quarter of double-digit adjusted earnings per share growth; GAAP EPS totaled $0.31 versus $0.16 in the prior year quarter, a 94% increase Our commitment to these values, underpinned by the execution of our four-pillar strategy, has led to 18 consecutive quarters of strong, double-digit adjusted earnings per share growth. In this regard, we remain very focused on our stated goal of $2.50 adjusted earnings per share by 2015, and we also expect strong double-digit EPS growth for many years to follow."